HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Reinhard Moidl Paul Simon Ernst Wolner Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moidl, R. Articles by Wolner, E. Search for Related Content PubMed PubMed Citation Articles by Moidl, R. Articles by Wolner, E. Related Collections Valve disease

Ann Thorac Surg 2002;74:S1312-S1317
© 2002 The Society of Thoracic Surgeons

---

Supplement: Cardiothoracic Techniques and Technologies

The On-X prosthetic heart valve at five years¹

^a Department of Cardiothoracic Surgery, University of Vienna, Vienna, Austria

* Address reprint requests to Dr Moidl, Department of Cardiothoracic Surgery, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
e-mail: reinhard.moidl{at}akh-wien.ac.at

Presented at the Eighth Annual Cardiothoracic Techniques and Technologies Meeting 2002, Miami Beach, FL, Jan 23–26, 2002.

BACKGROUND: Multicenter clinical trials were conducted in Europe and North America to evaluate the performance of the On-X bileaflet heart valve prosthesis (Medical Carbon Research Institute, Austin, TX).

METHODS: A total of 532 patients underwent implantation, 303 for aortic valve replacement (AVR) and 229 for mitral valve replacement (MVR), at 20 centers from September 1996 to July 2001. The study followed the guidelines of the AATS/STS. Mean follow-up was 23 months (total 1024 patient-years; maximum 5 years). Poolability analysis was performed to show the equivalence of the populations.

RESULTS: Patients and results were found to be similar and poolable. Freedom from adverse events at 2 years in the study were as follows: thromboembolism, 96.0% for AVR patients and 96.3% for MVR; thrombosis, 100% for AVR and 100% for MVR; bleeding events, 96.6% for AVR and 95.7% for MVR; and overall mortality, 95.2% for AVR and 92.4% for MVR. Median lactate dehydrogenate levels were in the normal range for AVR and MVR patients at all intervals. At 1 year, AVR echocardiographic results for the 19 to 25 valves, respectively, ranged from 1.5 to 2.8 cm² for effective orifice area and 9.2 to 4.7 mm Hg for mean gradient, and MVR effective orifice area by pressure half-time was 2.8 cm² and mean gradient was 4.2 mm Hg.

CONCLUSIONS: The two trials have given similarly excellent results for the On-X valve.

This article has been cited by other articles:

				V. Chan, W. R. E. Jamieson, B.-K. Lam, M. Ruel, H. Ling, G. Fradet, and T. G. Mesana Influence of the On-X mechanical prosthesis on intermediate-term major thromboembolism and hemorrhage: A prospective multicenter study J. Thorac. Cardiovasc. Surg., November 1, 2010; 140(5): 1053 - 1058.e2. [Abstract] [Full Text] [PDF]

				T. Gudbjartsson, T. Absi, and S. Aranki Mitral Valve Replacement Card. Surg. Adult, January 1, 2008; 3(2008): 1031 - 1068. [Full Text]

				U. Ozyurda, A. R. Akar, O. Uymaz, M. Oguz, M. Ozkan, C. Yildirim, A. Aslan, and R. Tasoz Early clinical experience with the On-X prosthetic heart valve Interact CardioVasc Thorac Surg, December 1, 2005; 4(6): 588 - 594. [Abstract] [Full Text] [PDF]